GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Cyclically Adjusted Price-to-FCF

Mesoblast (Mesoblast) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mesoblast Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mesoblast's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Cyclically Adjusted Price-to-FCF Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mesoblast's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mesoblast's Cyclically Adjusted Price-to-FCF falls into.



Mesoblast Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mesoblast's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Mesoblast's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0/125.6559*125.6559
=0.000

Current CPI (Dec. 2023) = 125.6559.

Mesoblast Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 0.000 95.473 0.000
201312 0.000 97.330 0.000
201406 0.000 98.352 0.000
201412 0.000 99.002 0.000
201503 0.000 99.187 0.000
201506 0.000 99.838 0.000
201509 -0.808 100.302 -1.012
201512 -0.527 100.673 -0.658
201603 -0.550 100.488 -0.688
201606 -0.452 100.859 -0.563
201609 -0.530 101.602 -0.655
201612 -0.630 102.159 -0.775
201703 -0.606 102.624 -0.742
201706 -0.518 102.809 -0.633
201709 -0.436 103.460 -0.530
201712 -0.300 104.110 -0.362
201803 -0.394 104.574 -0.473
201806 -0.404 104.945 -0.484
201809 -0.387 105.410 -0.461
201812 0.038 105.967 0.045
201903 -0.404 105.967 -0.479
201906 -0.364 106.617 -0.429
201909 -0.301 107.174 -0.353
201912 -0.032 107.917 -0.037
202003 -0.363 108.289 -0.421
202006 -0.252 106.246 -0.298
202009 -0.459 107.917 -0.534
202012 -0.007 108.846 -0.008
202103 -0.399 109.496 -0.458
202106 -0.280 110.332 -0.319
202109 -0.268 111.168 -0.303
202112 -0.267 112.654 -0.298
202203 -0.227 115.069 -0.248
202206 -0.203 117.112 -0.218
202209 -0.197 119.248 -0.208
202212 -0.212 121.477 -0.219
202303 -0.210 123.148 -0.214
202306 -0.196 124.170 -0.198
202309 -0.168 125.656 -0.168
202312 0.000 125.656 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mesoblast  (NAS:MESO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mesoblast Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mesoblast's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Industry
Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.